ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
about
Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancerDivergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor developmentInter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair researchBalance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLCKlotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathwayProteomics and biomarkers in clinical trials for drug developmentDecreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patientsDNA repair: from genome maintenance to biomarker and therapeutic target.Drug resistance and its significance for treatment decisions in non-small-cell lung cancer.Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study.Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cellsMetastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab.PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.Whole-genome approach implicates CD44 in cellular resistance to carboplatin.miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer.ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy.Repressing DNA repair to enhance chemotherapy: targeting MyD88 in colon cancer.Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.
P2860
Q24600990-F728A976-9397-45BA-8890-5C4B24DBA1DDQ28384678-2A61CC2C-FF41-4D7E-9FFD-6623F52DA603Q28388726-51006805-8B0B-42FD-90C6-6020BB825961Q28478252-6546D633-511F-4EC7-9611-ACC862D9C9FAQ28486480-EA4CFC1B-4900-434A-B583-8CD57EF22490Q30402667-FF900B64-6711-4F91-8D1E-827825C627F1Q33578400-6B462122-F6B4-49F2-A0FD-E77E7F12F077Q33699499-C3293854-093F-4F28-9246-DAC8F2387A7CQ33705325-936E2457-D069-45BC-B03B-B7B2E1EF3016Q33769990-ADB04D08-B117-4538-BD4F-4D2BA1B4090EQ34142322-91A921A5-17AC-4D2A-A92D-8B583ED15E49Q35196367-2FA7D8D5-8260-4659-96C4-574630DA4894Q35555880-AF008F52-B2D4-48EB-A3B8-587BF4A2BDE8Q36040613-82CE5099-568C-4803-AAF0-D63FF3187E0EQ36439434-B3A0AF2C-A5DB-46A2-945A-8380A85F4370Q36746536-01E73A80-AD2B-46FB-BBA7-20F274713A2AQ37290519-23A5A5A9-ED18-4CC4-B56C-1DE6B0827AF0Q37384203-A874C91E-8AFD-4CDA-8E38-13FE543F81C4Q37641671-AE23F732-3CD6-48A6-8947-CA40EACFEC48Q38958264-EA61BA85-B3C7-462D-9BB0-A76A31A18EE7Q39027918-EC5A7E5D-BE62-4942-BF41-8663F55FEA36Q39067495-C33BCE73-9E61-4DB9-AC0E-1C4FBD341909Q39540757-14F916B7-DF77-41E6-8689-C78144255139Q39891877-83AE62BE-158A-4045-9CBC-9DF2386CDDFEQ40466065-030759D9-2994-4143-9985-515B9E2AD2DFQ41318869-E70E6F35-0A02-455F-926B-4E49F548ABE8Q41961362-631AD85D-3FC8-433E-BAD5-DD9FA86AE5C0Q42284398-71DFDB7D-A574-4271-BFB5-E8917409AE3BQ42566962-7171A97C-1199-4187-A306-790E80ECF9B0Q43108358-20B36C2B-6FDC-4AA6-9D69-592CDCDA272EQ54374136-23467A73-955C-40A2-9B4E-A4D155AF9CFE
P2860
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@ast
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@en
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@nl
type
label
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@ast
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@en
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@nl
prefLabel
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@ast
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@en
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@nl
P1476
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
@en
P2093
Giannis Mountzios
Ken André Olaussen
P304
P356
10.1097/MCP.0B013E32816B5C63
P577
2007-07-01T00:00:00Z